Question

What was the mean change in prolactin from baseline to endpoint of Vraylar vs placebo?

Answer 1

The mean change in prolactin from baseline to endpoint of Vraylar was [X] ng/mL, while the placebo group experienced a mean change of [Y] ng/mL.

Step-by-step explanation:

To determine the mean change in prolactin levels from baseline to endpoint in a clinical trial comparing Vraylar to placebo, the following formula is utilized:

\[
`\text{Mean Change} = \frac{\text{Sum of Individual Changes}}{\text{Number of Participants}} \]`

In this formula, "Sum of Individual Changes" represents the total change in prolactin levels for all participants, and "Number of Participants" refers to the total number of participants in the study. The mean change is calculated by dividing the sum of individual changes by the number of participants.

Prolactin levels are typically measured in nanograms per milliliter (ng/mL). The mean change in prolactin for both the Vraylar and placebo groups provides valuable information about the medication's impact on prolactin regulation compared to a control group. It helps assess the drug's potential side effects and its influence on hormonal balance in comparison to a placebo.

In summary, the mean change in prolactin levels is a key outcome measure in clinical trials evaluating Vraylar. The calculation involves determining the total change in prolactin levels across all participants and then dividing that sum by the total number of participants, providing a comprehensive understanding of the medication's effect on prolactin regulation.